Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Hong
Frank S
FS
Mitchell
Catherine A
CA
Zantomio
Daniela
D
D000328:Adult; D000423:Alcian Blue; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D001853:Bone Marrow / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D004396:Coloring Agents; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D004396:Coloring Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006820:Hyaluronic Acid; D000423:Alcian Blue